The increasing diversity of infectious disease threats requires vaccine development systems that integrate antigen discovery, immunological characterization, epidemiological evidence, product-development efficiency, and disease-specific biological knowledge. This research paper develops an innovative conceptual approach for optimizing vaccine development for emerging infectious diseases and worldwide health needs through a structured synthesis of six provided studies. The methodology adopts a comparative literature-based framework rather than empirical experimentation, examining vaccinology principles, accelerated vaccine product life cycles, population-level sero-epidemiology, pathogen-specific epitope identification, host–pathogen interactions, and immunological indicators of disease. The analysis demonstrates that vaccine optimization cannot be reduced to a single technological intervention; rather, it requires coordination across discovery, candidate prioritization, preclinical reasoning, epidemiological targeting, development acceleration, and implementation-oriented evaluation. Particular attention is given to the role of immunological and hematobiochemical indicators in understanding disease dynamics, as illustrated by research on lumpy skin disease, while epitope-level investigations demonstrate the value of precise antigenic characterization. The proposed framework consequently positions vaccine development as an adaptive, evidence-integrated system in which biological specificity and development efficiency must operate simultaneously. The paper identifies opportunities for improving candidate selection, shortening development cycles, strengthening disease surveillance inputs, and aligning vaccine research with diverse global health requirements. Its principal contribution is a conceptual optimization architecture that connects fragmented stages of vaccine research into a coherent decision-oriented process.